找不到产品?留下需求帮您找
一键询价mda-mb-468+GFP+LUC 人乳腺癌细胞 XY-H776LGP
一周
4500¥
OCUM-1 人胃癌细胞 QCH777
一周
3500¥
Karpas422 人非霍奇金淋巴瘤 QCH778
一周
4000¥
CAL-33 人舌鳞癌细胞QCH779
一周
3000¥
MOLM16 人骨髓白血病细胞 QCH780
一周
4000¥
HLE-B3 人正常眼睛晶状体上皮细胞 QCH781
一周
5000¥
NOMO-1 人白血病细胞 QCH782
一周
3500¥
BPH-1 人前列腺增生细胞 QCH783
一周
4000¥
OCIM2 人急性粒细胞白血病 QCH784
一周
4000¥
GM12878 人B淋巴细胞 XY-H785
钦诚生物 | 一周
4000¥
公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述: 产品名称:Tipifarnib 产品别名:见爱必信官网 英文别名:Tipifarnib 靶点:Transferase CAS:192185-72-1 纯度:>98% 外观:见爱必信官网 保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -20℃ for six months. 描述: Tipifarnib(R115777)是一种有效的,特异性farnesyltransferase(FTase)抑制剂,作用于H-ras或N-ras突变细胞,具有最显著的抗增殖作用效果。与DMSO处理的LGL T细胞相比,用5 μM Tipifarnib处理72小时,凋亡细胞百分率明显高很多。使用健康捐赠者提供的T细胞,Tipifarnib按剂量依赖性降低IFNγ阳性细胞百分率。在沉淀物中,与DMSO相比,Tipifarnib降低激活型Ras的数量。 溶解性:Ethanol :9.8 mg/mL (20 mM) 体外研究: Using Tipifarnib 5 μM for 72 hours, the percentage of apoptotic cells is significantly higher in drug-treated compared to DMSO-treated LGL T-cells. Using T-cells from healthy donors, Tipifarnib reduces the percentage of IFNγ-positive cells in a time-dependent manner. Tipifarnib reduces the amount of activated Ras in precipitates compared to DMSO. Tipifarnib exerts selective in vitro toxicity against clonal MDS hematopoiesis at concentrations less than 10 nM the effect being more prominent in white cell progenitors. This action is not due to apoptosis induction as both normal and MDS progenitors displays equivalent DiOC3 and annexin V expression up to 72 hours after exposure to Tipifarnib. Combining Tipifarnib with 10 nM 4-OH-tamoxifen in the presence of E2 reduces the IC50 8-fold from 400 to 50 nM. Tipifarnib induces apoptosis in U937 cells. In addition, Tipifarnib inhibits isolated human farnesyltransferase for a lamin B peptide and for the K-RasB peptide with IC50 of 0.86 nM and 7.9 nM, respectively. 体内研究:Ki-67 is lower in the tumors treated with E2 withdrawal plus R115777 compared with E2 withdrawal alone. The combination of tamoxifen and R115777 results in significantly lower Ki-67 compared with either tamoxifen or R115777 alone (mean of 5% versus 16.9% and 67.3%, respectively). In contrast, no significant difference in apoptotic scores is seen between the treatment groups. R115777 alone also reduces the CTI compared with control. The combination of tamoxifen and R115777 or R115777 coupled with E2 withdrawal is most effective at lowering the CTI (0.8 and 0.7, respectively), which may account for the decrease in tumor volume.
产品信息订购:
|